Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABA NASDAQ:CGTX NASDAQ:IVVD NASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$3.46-4.3%$3.17$1.26▼$4.23$382.38M3.183.26 million shs540,792 shsCGTXCognition Therapeutics$1.13-6.3%$1.07$0.22▼$3.83$100.69M1.811.04 million shs295,211 shsIVVDInvivyd$1.31+12.5%$1.53$0.48▼$3.07$369.05M0.712.91 million shs2.36 million shsMNPRMonopar Therapeutics$60.48-0.8%$56.89$28.40▼$105.00$405.46M1.49223,445 shs35,571 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio+0.56%-9.75%+10.74%+28.93%+177.69%CGTXCognition Therapeutics0.00%+3.45%+23.03%+7.14%+259.82%IVVDInvivyd-21.09%-18.88%-27.95%-25.64%+38.77%MNPRMonopar Therapeutics-0.73%-2.31%+5.30%+9.97%+64.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$3.46-4.3%$3.17$1.26▼$4.23$382.38M3.183.26 million shs540,792 shsCGTXCognition Therapeutics$1.13-6.3%$1.07$0.22▼$3.83$100.69M1.811.04 million shs295,211 shsIVVDInvivyd$1.31+12.5%$1.53$0.48▼$3.07$369.05M0.712.91 million shs2.36 million shsMNPRMonopar Therapeutics$60.48-0.8%$56.89$28.40▼$105.00$405.46M1.49223,445 shs35,571 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio+0.56%-9.75%+10.74%+28.93%+177.69%CGTXCognition Therapeutics0.00%+3.45%+23.03%+7.14%+259.82%IVVDInvivyd-21.09%-18.88%-27.95%-25.64%+38.77%MNPRMonopar Therapeutics-0.73%-2.31%+5.30%+9.97%+64.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 2.63Moderate Buy$15.14338.29% UpsideCGTXCognition Therapeutics 2.50Moderate Buy$3.33196.30% UpsideIVVDInvivyd 2.33Hold$8.00513.03% UpsideMNPRMonopar Therapeutics 3.00Buy$107.0076.93% UpsideCurrent Analyst Ratings BreakdownLatest CGTX, CABA, MNPR, and IVVD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026CABACabaletta Bio Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$2.00 ➝ $4.005/14/2026IVVDInvivyd HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/4/2026CABACabaletta Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.004/29/2026IVVDInvivyd Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026MNPRMonopar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CABACabaletta Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/30/2026MNPRMonopar Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.003/27/2026CGTXCognition Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026CGTXCognition Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/24/2026CABACabaletta Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $16.003/24/2026CABACabaletta Bio Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$14.00 ➝ $13.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/ACGTXCognition TherapeuticsN/AN/AN/AN/A$0.33 per shareN/AIVVDInvivyd$53.43M6.91N/AN/A$1.04 per share1.25MNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$167.86M-$2.28N/AN/AN/AN/A-121.73%-90.19%N/ACGTXCognition Therapeutics-$23.49M-$0.24N/AN/AN/AN/A-72.68%-53.07%N/AIVVDInvivyd-$52.49M-$0.32N/AN/AN/A-98.25%-48.65%-34.48%N/AMNPRMonopar Therapeutics-$13.72M-$1.82N/AN/AN/AN/A-14.24%-13.93%N/ALatest CGTX, CABA, MNPR, and IVVD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A5/14/2026Q1 2026IVVDInvivyd-$0.08-$0.13-$0.05-$0.13$18.04 million$13.74 million5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8975-$0.46+$0.4375-$0.46N/AN/A5/7/2026Q1 2026CGTXCognition Therapeutics-$0.06-$0.05+$0.01-$0.05$4.40 millionN/A3/27/2026Q4 2025MNPRMonopar Therapeutics-$0.5123-$0.61-$0.0977-$0.61N/AN/A3/26/2026Q4 2025CGTXCognition Therapeutics-$0.06-$0.02+$0.04-$0.02N/AN/A3/23/2026Q4 2025CABACabaletta Bio-$0.45-$0.40+$0.05-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A2.772.77CGTXCognition TherapeuticsN/A5.923.45IVVDInvivydN/A7.247.24MNPRMonopar TherapeuticsN/A51.3651.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/ACGTXCognition Therapeutics43.35%IVVDInvivyd70.36%MNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipCABACabaletta Bio6.44%CGTXCognition Therapeutics14.40%IVVDInvivyd12.25%MNPRMonopar Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio50111.32 million104.16 millionOptionableCGTXCognition Therapeutics2089.50 million76.61 millionNot OptionableIVVDInvivyd100282.80 million248.16 millionOptionableMNPRMonopar Therapeutics106.70 million5.33 millionNot OptionableCGTX, CABA, MNPR, and IVVD HeadlinesRecent News About These CompaniesMonopar Therapeutics Reports Q1 2026 Financial Results and Updates on ALXN1840 Development for Wilson DiseaseMay 14 at 2:30 PM | quiverquant.comQMonopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 14 at 2:00 PM | globenewswire.comMonopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Wall Street ZenMay 9, 2026 | marketbeat.comMonopar Therapeutics (MNPR) Expected to Announce Earnings on TuesdayMay 5, 2026 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth PlansMay 4, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Agios Pharma (AGIO)April 22, 2026 | theglobeandmail.comMonopar Therapeutics Reports Positive Phase 3 Trial Results for ALXN1840 in Wilson Disease Patients at AAN Annual Meeting 2026April 19, 2026 | quiverquant.comQMonopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026April 19, 2026 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from BrokeragesApril 19, 2026 | marketbeat.comMonopar Therapeutics Inc (MNPR) Gets a Buy from JonesTradingApril 10, 2026 | theglobeandmail.comMonopar Therapeutics Inc. Reports Q4 and Full-Year 2025 Financial Results and Highlights Progress for ALXN1840 in Wilson DiseaseMarch 27, 2026 | quiverquant.comQMonopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateMarch 27, 2026 | globenewswire.comMonopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy OfficerMarch 2, 2026 | globenewswire.comMonopar Therapeutics scores relative strength rating upgrade; hits key thresholdFebruary 24, 2026 | msn.comInstitutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them.February 11, 2026 | finance.yahoo.comStocks showing improved relative strength: Monopar TherapeuticsFebruary 9, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Monopar Therapeutics Inc (MNPR) and Connect Biopharma Holdings (CNTB)January 16, 2026 | theglobeandmail.comMorgan Stanley initiates coverage of Monopar Therapeutics (MNPR) with overweight recommendationJanuary 10, 2026 | msn.comMonopar Therapeutics (NASDAQ:MNPR) CFO Quan Anh Vu Acquires 1,500 SharesDecember 30, 2025 | insidertrades.comWhat Awaits These 4 Biotech Stocks That More Than Doubled in 2025December 22, 2025 | zacks.comIs Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount?November 22, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGTX, CABA, MNPR, and IVVD Company DescriptionsCabaletta Bio NASDAQ:CABA$3.46 -0.16 (-4.29%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Cognition Therapeutics NASDAQ:CGTX$1.12 -0.08 (-6.25%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Invivyd NASDAQ:IVVD$1.30 +0.15 (+12.50%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Monopar Therapeutics NASDAQ:MNPR$60.48 -0.51 (-0.84%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
